Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

BridgeBio Pharma (BBIO) EBT Margin: 2019-2025

Historic EBT Margin for BridgeBio Pharma (BBIO) over the last 7 years, with Sep 2025 value amounting to -154.50%.

  • BridgeBio Pharma's EBT Margin rose 585773.00% to -154.50% in Q3 2025 from the same period last year, while for Sep 2025 it was -215.80%, marking a year-over-year decrease of 2680.00%. This contributed to the annual value of -244.34% for FY2024, which is 677760.00% up from last year.
  • Latest data reveals that BridgeBio Pharma reported EBT Margin of -154.50% as of Q3 2025, which was down 0.72% from -153.40% recorded in Q2 2025.
  • In the past 5 years, BridgeBio Pharma's EBT Margin registered a high of 21,754.94% during Q4 2021, and its lowest value of -43,350.30% during Q3 2022.
  • For the 3-year period, BridgeBio Pharma's EBT Margin averaged around -4,143.47%, with its median value being -4,258.25% (2023).
  • Data for BridgeBio Pharma's EBT Margin shows a peak YoY increase of 13,487,215bps (in 2021) and a maximum YoY decrease of 4,088,617bps (in 2021) over the last 5 years.
  • Over the past 5 years, BridgeBio Pharma's EBT Margin (Quarterly) stood at 21,754.94% in 2021, then plummeted by 2,951,590bps to -7,760.96% in 2022, then slumped by 324,798bps to -11,008.94% in 2023, then surged by 648,266bps to -4,526.28% in 2024, then soared by 585,773bps to -154.50% in 2025.
  • Its EBT Margin was -154.50% in Q3 2025, compared to -153.40% in Q2 2025 and -121.00% in Q1 2025.